Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference

Anticipated 2024 milestones include: present reni-cel clinical data updates mid-year and year-end, initiate the RUBY clinical trial adolescent cohort, establish in vivo preclinical proof-of-concept for an undisclosed indication, and continue to sublicense foundational IP

Strong financial position with operational runway into 2026

Company to present at the 42^nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9 at 4:30 p.m. PST

CAMBRIDGE, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that Gilmore O’Neill, M.B., M.M.Sc., President and Chief Executive Officer, will discuss the Company’s 2024 strategic priorities and anticipated milestones at the 42^nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, at 4:30 p.m. PST.

In his remarks, Dr. O’Neill will discuss several components of the Company’s strategic priorities and progress, including an unchanged focus on developing renizgamglogene autogedtemcel (reni-cel) towards biologics licensing application (BLA) and commercialization, building an in vivo pipeline, and increasing business development activities, including continuing to sublicense the Company’s foundational Cas9 and Cas12a gene editing technology.

Dr. O’Neill will also discuss the Company’s anticipated 2024 milestones:

• Continue enrollment and dosing in the RUBY and EdiTHAL clinical trials of reni-cel,
• Initiate the adolescent cohort in the RUBY trial,
• Present a substantive clinical data set of sickle cell patients with considerable clinical follow-up in the RUBY trial in mid-2024 and by year-end 2024,
• Establish in vivo preclinical proof-of-concept for an undisclosed indication, and
• Derive revenue from the Company’s foundational IP, building on the recently announced license agreements with Vertex Pharmaceuticals and Vor Bio.
  

“2023 was a pivotal year for Editas as we launched and executed our focused strategy, strengthened our leadership team, and hit multiple clinical milestones to drive Editas’ transformation towards a commercial-stage company. We expect 2024 to be even more eventful as we continue to develop our potentially transformative experimental medicines,” said Dr. O’Neill.

He continued, “As a pioneer in the genome editing field, we remain focused on driving solutions for people living with serious, previously untreatable diseases by leveraging our world-class gene editing platform – in the form of developing our own clinically differentiated medicines and in the form of licenses and sublicenses to other pharmaceutical and biotechnology companies developing medicines. To be a part of this chapter of Editas’ journey is invigorating, and I look forward to what’s next.”